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Medulloblastomas are the most common type of primitive
neuroectodermal tumours observed in the central nervous system
of children. In spite of recent advances in therapy, including
microsurgery, combined chemotherapy and radiotherapy, the long-
term prognosis for patients with these tumours is not satisfactory
(Evans et al, 1990), pointing to a need for more specific and 
efficient therapies. Antibodies that recognize medulloblastoma
cells are expected to act as diagnostic and therapeutic reagents.
Therefore, we attempted to produce a medulloblastoma-specific
monoclonal antibody (MAb). Immunization of mice with ONS-76
medulloblastoma cells (Tamura et al, 1989) successfully produced
the antibodies referred to as ONS-M21 MAb (Moriuchi et al,
1993). ONS-M21 MAb reacted with a surface antigen of most
glioma and medulloblastoma cell lines, and it also reacted with
surgical specimens of gliomas and medulloblastomas. On the
other hand, this MAb did not show cross-reactivity with peripheral
blood cells or normal brain tissue. However, mouse antibodies are
highly immunogenic in humans, and, hence, their clinical use may
be limited. We genetically engineered a recombinant, humanized
version of ONS-M21 MAb (hONS-M21 Ab) by means of CDR
grafting (Ohtomo et al, 1995) in order to eliminate immuno-
genicity. This humanized Ab competed with ONS-M21 MAb for
binding to glioma cells. In addition, this Ab, when labelled with an
isotope, was capable of depicting tumour location by an auto-
radiographic technique. Thus, humanized Ab possesses various
advantages that make it attractive for clinical applications.
As the target molecule of ONS-M21 remains unknown, identifi-
cation of this antigen is a necessary step before any clinical use of
this antibody can be attempted. In the present study, we purified
ONS-M21 antigen from ONS-76 cell lysates by means of an Ab-
binding affinity column, analysed the amino acid sequences of the
ONS-M21 binding protein and identified the target molecule of
ONS-M21 MAb. In addition, the mRNA level of this antigen was
analysed by reverse transcription–polymerase chain reaction (RT-
PCR) in surgical specimens of gliomas and medulloblastomas.
MATERIALS AND METHODS
Cell culture conditions and preparation of the
monoclonal antibody
The human medulloblastoma cell line ONS-76 was established in
our laboratory (Tamura et al, 1989; Institution for fermentation,
Osaka, No. 50355), maintained in Dulbecco’s modified Eagle
medium (DMEM) with 10% heat-inactivated fetal bovine serum
(FBS) and 50mg ml–1 gentamycin, and incubated in a humidified
10% carbon dioxide-in-air atmosphere at 37°C. ONS-76 cells
were collected using a cell scraper and washed with cold Tris-
buffered saline (TBS; 10mmol l–1 Tris-Cl, 150mmol l–1 NaCl, 
pH 8.0). The cells were resuspended in a detergent solution (TBS
with 0.5% Tween-20 and 1mg ml–1 p-amidinophenyl methane-
sulphonyl fluoride hydrochloride) at a concentration of 106 cells
ml–1, and then shaken for 2h at 4°C to elute the cell extract. After
centrifuging (3000r.p.m., 20min), the supernatant was collected
as cell extract and stored at –80°C.
ONS-M21 MAb (IgG1) was purified as previously described
(Moriuchi et al, 1993).
IMMUNOPRECIPITATION
To label ONS-76-producing proteins with [35S]methionine, ONS-
76 cells were preincubated overnight in methionine-free MEM
(ICN Biomedicals, Costa Mesa, CA, USA), and then cultured in
methionine-free MEM with 10% FBS and 100mCi ml–1 of an L-
[35S] in vivo cell labelling mix (Amersham, Buckinghamshire,
UK) for 5h in a humidified 10% carbon dioxide-in-air atmosphere
at 37°C. The cell extract was then obtained as described above.
This cell extract (1ml) was preincubated with 50ml of protein
A–Sepharose (Pharmacia, Uppsala, Sweden) conjugated with
rabbit anti-mouse IgG1 (Cappel, Durham, NC, USA) for 1h at
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Correspondence to:K Shimizu4°C. After centrifuging, the supernatant was incubated at 4°C with
80 mg of ONS-M21 MAb for 1 h and then with 50 ml of protein
A–Sepharose conjugated with rabbit anti-mouse IgG1 for 1 h at
4°C. In order to compare this antibody with another commercially
available antibody (P1B5; Dakopatts, Glostrup, Denmark) that
recognizes integrin a3, the cell extract was preimmunoprecipi-
tated with P1B5 Ab instead of ONS-M21 MAb, centrifuged and
the supernatant reimmunoprecipitated with ONS-M21 MAb. The
final immunoprecipitate was washed five times with TBS and then
boiled in sample buffer containing 62.5 mM Tris-Cl (pH 6.8), 10%
glycerol, 2% sodium dodecyl sulphate (SDS), 2% 2-mercapto-
ethanol and 0.1% bromophenol blue for 5 min to separate protein
A–Sepharose and rabbit immunoglobulins. The precipitate was
applied to a 6% SDS polyacrylamide gel electrophoresis 
(SDS-PAGE). The dried gel was autoradiographed by exposure to
a BAS-IIIs imaging plate (Fuji Photo Film, Tokyo, Japan) for 12 h
and analysed with BAS 1000 (Fuji Photo Film). The negative
control was incubated with non-immune mouse IgG1 (Tago
Company, Burlington, CA, USA) instead of ONS-M21.
Purification of ONS-M21 antigen
To obtain a sufficient amount of the antigen, 1.2 ´ 1010 cells were
lysed as described above. The cell extract was dialysed to decrease
the Tween-20 concentration to 0.1%. Cyanogen bromide (CNBr)-
activated Sepharose (Pharmacia) was coupled with 20 mg of
ONS-M21 monoclonal antibody and the coupled gel was
embedded into a column (0.8 ´ 5 cm) and kept at 4°C. The cell
extract was applied to the column at a rate of 5–10 ml h–1. After
washing the column with 1000 ml of TBS containing 0.1%
Tween-20, bound proteins were eluted in 500-ml fractions with
0.05 M glycine, 0.1% Tween-20 and 0.5 M sodium chloride (pH
2.5) at a flow rate  of 8 ml h–1, and then immediately neutralized
with 1 M Tris-Cl  (pH 8.0). To estimate the concentration of the
target protein, 10 ml of each fraction was blotted onto a nitrocellu-
lose membrane and analysed by dot-blot enzyme-linked
immunosorbent assay (ELISA) using 30 mg ml–1 ONS-M21 as the
primary antibody and 1:500 of peroxidase-conjugated goat anti-
mouse IgG (Zymed,  San Francisco, CA, USA) as the secondary
antibody. Immunocomplexes were revealed using the ECL system
(Amersham) and the absorbency was measured using the Image
Quant program (Molecular Dynamics, Sunnyvale, CA, USA).
Positive fractions were mixed together, dialysed in TBS
containing 0.1% Tween-20, and reapplied to the affinity column.
The bound protein was eluted and analysed as described above.
Positive fractions were used for amino acid sequence analysis.
Analysis of the amino acid sequence of the ONS-M21
antigen
The eluted sample was condensed 30-fold using a Centricon 50
concentrator (Amicon, Beverly, MA, USA). To analyse the amino-
terminal amino acid sequence, 10% of the sample was separated
by SDS-PAGE and electroblotted (1 mA cm–2, 90 min) onto a
PVDF membrane (Bio-Rad, Hercules, CA, USA). The membrane
was stained with 0.1% Ponceau S and 2% acetic acid. The main
band (140 kDa) was cut out and the N-terminal amino acid
sequence of the isolated peptide was analysed on a protein
sequencer (476A Protein Sequencer, Applied Biosystems). To
digest the protein at methionine residues, the isolated band was
dissolved in 70% formic acid containing 2 mg of CNBr and then
incubated for 18 h at room temperature. The suspension was
concentrated and dried by the spin-vacuum method. The digested
peptide sample was resuspended in 0.1% trifluoroacetic acid and
separated by microbore high-performance liquid chromatography
(HPLC) on a Vydac C18 column (5 mm, 2.1 ´ 250 mm; Vydac,
Hesperia, CA, USA) using an increasing concentration gradient of
acetonitrile (0–90%, 0.2 ml min–1, 0.9% min–1). Each peak was
analysed by the sequencer.
Immunohistochemistry
Surgical specimens of gliomas and medulloblastomas were
embedded in OCT compound (Tissue Tek, Miles, IN, USA) 
and immediately frozen. Immunohistochemical analysis was
performed according to the previously described method
(Moriuchi et al, 1993). In brief, specimens were fixed with
acetone, blocked with gout normal serum, and incubated with
primary Abs, such as ONS-M21 MAb, anti-Mac-1 Ab
(PharMingen, SanDiego, CA, USA), or anti-glial fibrillary acid
protein (GFAP) Ab (Dakopatts). Then, biotinylated goat anti-
mouse or anti-rabbit IgG (Dakopatts) was added as secondary Ab,
the samples were washed with PBS, incubated with strepta-
vidin–biotin–peroxidase complex, and immunocomplexes were
revealed by the peroxidase reaction using 0.06% diaminobenzi-
dine with 0.01% hydrogen peroxidase in 50 mM Tris-HCl buffer
(pH 7.0).
Isolation of total RNA and reverse transcription
Surgical specimens were treated with Isogen (Nippongene, Tokyo,
Japan) and the total RNA was extracted according to the protocol
provided by the manufacturer. Total RNA (10 mg) was converted
to cDNA using oligo-dT primer pd(T)12–18 (0.5 mg, Invitrogene,
San Diego, CA, USA) as a primer and avian myeloblastosis virus
(AMV) reverse transcriptase (28 units, Seikagaku Kogyo, Tokyo,
Japan) in 30 ml of reverse transcription buffer containing 50 mM
Tris-HCl (pH 8.3), 100 mM potassium chloride, 10 mM magne-
sium chloride, and 600 mM of each dNTP (dATP, dCTP, dGTP and
dTTP, Perkin Elmer Cetus, Norwalk, CT, USA), 10 mM dithio-
threitol and 10 units of ribonuclease inhibitor (Takara, Kyoto,
Japan). The reaction mixture was incubated at 42°C for 50 min,
heated at 70°C for 10 min, chilled on ice and then stored at –20°C.
Polymerase chain reaction of cDNA
On the basis of published sequences (Takada et al, 1991; Tsuji et al,
1991), we prepared pairs of oligonucleotide primers corresponding
to sequences of the integrin a3 gene and the housekeeping
gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a
control. The following gene-specific oligo-nucleotide primers
were used: integrin a3 (2154–2173) sense primer 5¢-GCCAAGC-
TAATGAGACCATC-3¢, antisense primer (2742–2761) 5¢-TCAG-
CACGAGTGCTCGAGACTTG-3¢, GAPDH (211–231) sense
primer 5¢-CCCATCACCATCTTCCAGGAG-3¢, antisense primer
(475–495) GTTGTCATGGATGACCTTGGC-3¢. The amplified
products of integrin a3 and GAPDH were 608 and 285 bp
respectively.
One-thirtieth of the RT reaction mixture was used as a source of
cDNA. Each polymerase chain reaction (PCR) (100 ml) contained
40 pmol of each primer, 2.5 units of Taq polymerase (Amplitaq
Gold, Perkin Elmer Cetus), 160 mmol/l–1 of each dNTP, 10 ml of 
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reaction was performed in a PCR thermal cycler (Perkin Elmer
Cetus). After preheating the mixture at 95°C for 9 min, the mate-
rial for PCR was denatured at 94°C for 1 min, annealed at 55°C for
1 min and extended at 72°C for 2 min. Typically, 25–40 cycles of
amplification were performed. PCR products were size fraction-
ated by gel electrophoresis through 2% agarose. The density of the
separated bands was evaluated using Image Quant (Molecular
Dynamics).
RESULTS
Molecular weight of the ONS-M21 antigen
In order to determine the molecular weight of the ONS M-21
antigen, we performed immunoprecipitation of 35S-labelled cell
extracts of ONS-76 with ONS-M21 MAb. Autoradiography of the
sample revealed a 140-kDa band, which was not detected in the
negative control lane (Figure 1, lanes 2 and 3). Other weak bands
were seen in both lanes. We therefore verified that ONS-M21
MAb recognizes the 140-kDa protein.
Separation of eluted fractions from the affinity column
Portions of the eluted fractions from the ONS-M21 mAb-fixed
affinity column were blotted onto a nitrocellulose membrane 
and analysed by the dot-blot ECL system (Amersham). The
absorbency of the blots was measured and fractions 10–16 were
found to be positive (Figure 2A). A part of the collected sample
was separated by SDS-PAGE and stained with silver. One major
band migrating with a molecular weight of 140 kDa and one minor
band of about 38 kDa were detected (Figure 2B).
Amino acid sequence analysis reveals ONS-M21
antigen to be integrin a3
About 10% of the purified sample was concentrated and separated
by SDS-PAGE. The main band (140 kDa) was then cut out and the
amino acid sequence was analysed. Nineteen of the 20 amino acids
from the amino terminus were identified (Figure 3). A homology
search revealed that the 18-amino-acid sequence was identical to
the amino-terminal sequence of human integrin a3 (Takada et al,
1991; Tsuji et al, 1991).
The cyanogen bromide-treated sample was applied to a HPLC
column to separate the digested peptides. Although many peaks
were detected, five peptides were chosen for amino acid sequence
analysis. All of the identical sequences showed complete matches
with the internal sequence of integrin a3 (Figure 3; Takada et al,
1991; Tsuji et al, 1991).
ONS-M21 MAb recognizes the same antigen as the
commercially available anti-integrin a3 Ab
We performed immunoprecipitation with ONS-M21 MAb and
commercially available anti-integrin a3 Ab, P1B5 Ab, from 35S-
labelled cell extracts of ONS-76. Both Abs recognized a protein
with a molecular weight of 140 kDa (Figure 1, lanes 3 and 4). The
supernatant of the cell extract, which had been already immuno-
precipitated with P1B5 Ab, was reimmunoprecipitated with ONS-
M21 MAb. The 140-kDa band in lane 5 of Figure 1 was extremely
faint compared with that of lane 3. This suggests that P1B5 Ab and
ONS-M21 MAb interact with a common antigen.
Protein expression and mRNA transcription of the
ONS-M21 antigen gene in surgical specimens of
gliomas and medulloblastomas
Surgical specimens of gliomas and medulloblastomas were classi-
fied according to the histological classification of tumours of the
central nervous system (Daumas-Duport et al, 1988; Kleihues and
Burger, 1993). In tumour specimens of grade II gliomas, scattered
staining with ONS-M21 MAb was immunohistochemically
observed (Figure 4A). The number of positive cells increased in
grade III gliomas (data not shown). Many positive cells were
detected in glioblastoma (grade IV) (Figure 4B). In surgical speci-
mens, cells recognized by ONS-M21 MAb were not positively
stained with anti-Mac-1 Ab and anti-GFAP Ab (Figure 4D and E).
All things considered, these cells would appear not to be
microglial cells or reactive astrocytes, but rather tumour cells.
As surgical specimens do not always suffice to purify a suffi-
cient amount of RNA, RT-PCR had to be used instead of Northern
blotting analysis. To determine the appropriate number of cycles
for quantitative evaluation of the amount of cDNA, the correlation
between the PCR cycle number and the amount of RT-PCR
product was examined. Through preliminary evaluation, we chose
25 cycles of PCR for GAPDH cDNA and 35 cycles for integrin a3
cDNA. These RT-PCR products were mixed at a GAPDH to inte-
grin a3 volume ratio of 0.5, and they were separated using 2%
agarose gel electrophoresis (Figure 5A). Integrin a3 mRNA tran-
scription expressed as a ratio of that of the housekeeping gene
GAPDH is shown in Figure 5. There was a tendency for integrin
a3 mRNA transcription to increase with the glioma grade of
malignancy (Figure 5B).
DISCUSSION
In this report, we have demonstrated that the target molecule of
monoclonal antibody ONS-M21 is human integrin a3. The molec-
ular weight of this antigen was previously reported to be 90-kDa
ONS-M21 antibody recognizes integrin a3 335
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Figure 1 Molecular weight of the ONS-M21 MAb-recognized antigen.
Whole-cell extracts of ONS-76 that were labelled with [35S]methionine were
immunoprecipitated with ONS-M21 MAb or P1B5 Ab or control mouse IgG.
The precipitates were then analysed using 6% SDS-polyacrylamide gels.
Lane 1, molecular weight standards; molecular weights are indicated in kDa.
Lane 2, ONS-76 extract incubated with control IgG. Lane 3, ONS-76 extract
incubated with ONS-M21 MAb. Lane 4, ONS-76 extract incubated with P1B5
Ab. Lane 5, ONS-76 extract incubated with ONS-M21 MAb following
immunoprecipitation with P1B5 Abprotein (Moriuchi et al, 1993), which is at least 50 kDa smaller than
the integrin a3 detected in this report. This discrepancy turns out to
be due to an error of the molecular weight marker in the previous
report. Hence, the exact molecular weight should now be considered
to be 140 kDa, as described in this report (Figure 1). Two molecular
species of protein were adsorbed to the ONS-M21 MAb-binding
column (Figure 2). Sequence analysis revealed the protein of the
major band to be integrin a3. This analysis also demonstrated that
the other 38-kDa protein had homology with the P32 subunit of pre-
mRNA splicing factor SF2 (Honore et al, 1993). However, no
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Figure 2 Purification of ONS-M21 antigen. (A) The antigen recognized by ONS-M21 MAb from ONS-76 cell extracts was purified using ONS-M21 MAb-fixed
affinity chromatography. The bound protein was eluted with acid buffer and the antigen concentration of each fraction was determined by immunoblotting using
an ECL system. Squares represent the absorbency of dot blots. Circles represent the pH of the eluted samples. (B) SDS-PAGE of the ONS-M21 antigen
purified using ONS-M21 MAb-affinity column chromatography. Positive samples of ECL dot blots were mixed together, condensed, separated by 7.5% SDS-
PAGE and stained with silver. Lane 1, molecular weight standards; molecular weights are in kDa. Lane 2, eluted sample
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Figure 3 Amino acid sequence of ONS-M21 antigen. (A) CNBr-digested peptide map of the protein eluted from the ONS-M21 affinity column. The bound
protein was treated with 70% formic acid containing 2 mg of CNBr. The peptides were dissolved in 0.1% trifluoroacetic acid and analysed by HPLC. The amino
acid sequences of p9, 10, 12 and 13 were obtained. (B) The sequences of the amino-terminal and internal domains were obtained from the purified antigen.
The sequences were aligned with residues 1–20, 75–89, 527–539, 541–547, 735–747 and 754–771 of the deduced amino acid sequence of integrin a3. TM,
transmembrane region of integrin a3; N, amino-terminal; C, carboxy-terminalpositive band other than the 140-kDa band was detected by immuno-
precipitation. We also purified this antigen from the subcutaneously
transplanted ONS-76 cells of nude mice. SDS-PAGE and silver
staining revealed the presence of the 140-kDa band but no 38-kDa
band was detected (data not shown). Commercially available P1B5
Ab, which recognized integrin a3, could precipitate the same molec-
ular weight protein as ONS-M21 MAb (Figure 1). In the competitive
immunoprecipitation experiment, prior treatment of the samples
with P1B5 Ab resulted in failure of ONS-M21 MAb to precipitate
the antigen, suggesting that P1B5 Ab and ONS-M21 MAb compete
for the same antigen (Figure 1). These results, taken together,
suggest that the ONS-M21 antigen is identical to integrin a3.
According to the literature, integrin a3 is not distributed on
oligodendrocytes, ependymal cells, neurons or microglias (Paulus
et al, 1993). Our experiment showed that cells recognized by
ONS-M21 MAb are neither microglias nor reactive astrocytes
(Figure 4). This also supports the idea that ONS-M21 MAb reacts
with integrin a3 expressed on glioma cells.
Furthermore, to investigate for mutations of this protein
expressed in glioma cells, we examined the cDNA sequence of the
ONS-M21 antibody recognizes integrin a3 337
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CD
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Figure 4 Immunohistochemical staining of glioma specimens. (A) Grade II
glioma with ONS-M21 MAb. (B) Grade IV glioma with ONS-M21 MAb. (C, D
and E) are the same section from adjacent slices of grade II glioma. (C) With
ONS-M21 mAb. (D) With anti-Mac-1 Ab. (E) With anti-GFAP Ab. (A and B)
Original magnification ´200. (C, D and E) Original magnification ´100
A Bcoding region of integrin a3 in five glioma cell lines. No common
cDNA mutations causing amino acid replacements or deletions
were detected among these cell lines (data not shown). These find-
ings suggest that ONS-M21 MAb recognizes the normal form of
integrin a3 expressed in these glioma cell lines.
Many monoclonal antibodies against gliomas, prepared by
immunizing mice with glioma cells, have been reported. Some of
those antibodies have been analysed with regard to their target
molecules (Schold et al, 1993; Okada et al, 1994; Romejin et al,
1994). Mouse MAbs against gliomas have also been applied in
experimental models. Some Abs were expected to have an anti-
tumour effect by themselves (Dastider and Sharma, 1995), and
others were used in combination with a radioisotope (Williams 
et al, 1990) or chemotherapeutic agent (Schrappe et al, 1992).
Furthermore, some MAbs have also been applied to clinical diag-
nosis and therapies, even though these Abs were derived from
mice (Daghighian et al, 1993; Schold et al, 1993; Faillot et al,
1996). Human Ab is preferred for clinical applications because
mouse Ab can be more immunogenic than human Ab. Although
human MAbs against gliomas have been produced, their target
molecules have not been reported (Dan et al, 1992, 1995).
Recombinant humanized ONS-M21 Ab has already been success-
fully produced (Ohtomo et al, 1995), and therefore hONS-M21 Ab
is the only Ab against gliomas whose target molecule has been
identified. The expression of integrin a3 in the normal brain has
been reported to be very low or even undetectable (Fradet et al,
1984; McGeer et al, 1990; Paulus et al, 1993), and ONS-M21
MAb is not reactive to either fetal or adult brain tissues (Moriuchi
et al, 1993). A significant amount of ONS-M21 MAb attached to
the cell surface was rapidly internalized into the cytoplasm, and
the A-chain of ricin-conjugated ONS-M21 MAb displayed glioma
specific cell toxicity in vitro (Shimizu et al, 1998). 125I-labelled
hONS-M21 Ab was found to accumulate in the glioma of nude rat
brains 24 h after intravenous administration (data not shown). In
this way, hONS-M21 Ab is attractive for clinical applications such
as for pathological diagnosis or glioma-specific targeting.
Integrin  a3 is one of the adherent molecules that binds to
collagen, laminin and fibronectin (Elices et al, 1991; Takeda et al,
1991), although it is still controversial as to whether integrin a3
induces cell–cell adhesion (Shiramarao et al, 1993; Weitzmen et
al, 1995). The expression of integrin a3 in fibroblasts increases
following oncogenic transformation (Tsuji et al, 1991). In malig-
nant tumours, poorly differentiated hepatocellular carcinomas
show down-regulation of integrin a3 (Jaskiewicz and Chasen,
1995), an abundant expression of which is related to the mode 
of gastric and colorectal cancer invasion (Boku et al, 1995).
Furthermore, transfection with cDNA coding for integrin a3
reduced the tumorgenicity of rhabdomyosarcoma cells (Weitzman
et al, 1996). Thus, the expression of integrin a3 is different
depending on the type of cancer and the level of malignancy.
Although immunohistochemical analysis of integrin a3 in gliomas
has been demonstrated (Paulus et al, 1993), no quantitative evalu-
ation has been reported. In the present study, we quantified inte-
grin a3 mRNA by an RT-PCR method using GAPDH genes as an
internal control, in accordance with previous reports (Suzuki et al,
1995; Zhao et al, 1995). The results showed that integrin a3 was
transcribed in all gliomas and medulloblastomas and that the
amount of integrin a3 increased with the grade of the malignancy.
The results of this study suggest that integrin a3 may play some
role during the development of malignancy in glioma, such as
invasion or infiltration of the surrounding brain. It would be inter-
esting to investigate the pathophysiological mechanisms of the
ONS-M21 antigen, which we have shown in this report to be 
integrin  a3.
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